A nanobody for the detection of atherosclerosis, its preparation method and application
By developing anti-ALDH4A1 nanobodies and establishing a double-antibody sandwich ELISA detection system, the problem of difficulty in quantitative detection of ALDH4A1 in existing technologies has been solved, realizing the specific identification and quantitative detection of ALDH4A1 in plasma, supporting early screening and auxiliary diagnosis of atherosclerosis.
Patent Information
- Application Number
- CN202611593635.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2026-10-15
- Publication Date
- 2026-11-17
AI Technical Summary
The lack of high-affinity nanobodies that can specifically recognize and bind to ALDH4A1 in existing technologies makes it difficult to quantitatively detect ALDH4A1 in plasma, thus hindering early serological screening and auxiliary diagnosis of atherosclerosis.
A nanobody against ALDH4A1 was developed by extracting total RNA from peripheral blood mononuclear cells of camels, reverse transcribing it to obtain cDNA, constructing a phage display library, screening positive clones with the strongest binding signal through biopanning, recombinantly expressing and purifying the nanobody, and establishing a double-antibody sandwich ELISA detection system for quantitative detection.
It achieves specific identification and quantitative detection of ALDH4A1 in plasma, with a linear detection range of 9.7~625 ng/mL and a limit of detection of 6.64 ng/mL. The intra-batch and inter-batch recovery rates meet industry standards and can be used for early screening and auxiliary diagnosis of atherosclerosis.
Smart Images

Figure CN123106910A_ABST
Abstract
Description
Technical Field
[0001] This invention relates to the field of biomedical technology, specifically to a nanobody for the detection of atherosclerosis, its preparation method, and its application. Background Technology
[0002] Atherosclerosis is a chronic inflammatory disease characterized primarily by the formation of plaques in the arterial intima. If the condition continues to progress, it will develop into cardiovascular disease. The mortality burden caused by cardiovascular disease has surpassed that of malignant tumors, becoming a major public health challenge threatening human health, and has long been the leading cause of death in my country. Therefore, early detection and early intervention of atherosclerosis have significant clinical and public health value.
[0003] Currently, the clinical diagnosis of atherosclerosis mainly relies on imaging techniques such as color Doppler ultrasound, coronary angiography, chest X-ray, and vascular ultrasound. These imaging methods are mostly invasive or require special operating conditions, making them difficult to implement for large-scale population screening. Furthermore, by the time a positive result is detected, the lesions have often progressed to the middle or late stages, with irreversible narrowing of the blood vessels. Current technologies cannot provide early risk warnings or stratification in the early stages of the disease. Therefore, identifying specific serological markers for atherosclerosis and establishing simple, non-invasive, and large-scale screening methods for early diagnosis are of significant clinical importance in reducing the disability and mortality rates of cardiovascular diseases.
[0004] ALDH4A1 (mitochondrial dehydrogenase, member A1 of the aldehyde dehydrogenase 4 family) is a novel atherosclerosis-related autoantigen discovered in recent years. Lorenzo et al. (Nature, 2021, 589:287-292) found that ALDH4A1 is a B-cell autoantigen in atherosclerotic lesions, abnormally highly expressed in atherosclerotic plaques. Studies indicate that ALDH4A1 plays a crucial regulatory role in the development and progression of atherosclerosis; it is not only a diagnostic biomarker for atherosclerosis but also a potential therapeutic target.
[0005] However, the clinical translation of ALDH4A1 as a serological biomarker depends on the availability of high-affinity antibodies capable of specifically recognizing and binding to ALDH4A1. Currently, antibody research targeting ALDH4A1 is extremely limited, and there are no reports of anti-ALDH4A1 nanobodies. Traditional monoclonal antibody preparation methods are time-consuming, costly, and have poor tissue penetration, making it difficult to meet the requirements of low-cost, high-stability diagnostic reagents for large-scale clinical screening.
[0006] Therefore, developing high-affinity nanobodies targeting ALDH4A1, establishing a nanobody-based quantitative detection method for ALDH4A1, and exploring its application in the diagnosis and treatment of atherosclerosis are urgent technical problems to be solved in this field. Summary of the Invention
[0007] The purpose of this invention is to overcome the shortcomings of the prior art and provide a nanobody for the detection of atherosclerosis, its preparation method and application, and to solve the technical problem that "the prior art lacks high-affinity nanobodies that can specifically recognize and bind to ALDH4A1, making it difficult to quantitatively detect ALDH4A1 in plasma, and thus difficult to achieve early serological screening and auxiliary diagnosis of atherosclerosis".
[0008] To achieve the above objectives, the present invention is implemented using the following technical solution: In a first aspect, the present invention provides a nanobody for the detection of atherosclerosis, wherein the nanobody (anti-ALDH4A1 nanobody) comprises complementarity-determining regions CDR1, CDR2 and CDR3; The amino acid sequence of CDR1 is shown in SEQ ID NO:3, the amino acid sequence of CDR2 is shown in SEQ ID NO:5, and the amino acid sequence of CDR3 is shown in SEQ ID NO:7.
[0009] Specifically, the amino acid sequence of the nanobody is as shown in SEQ ID NO:1, or an amino acid sequence that has at least 70%, 80%, 90%, 95% or 99% sequence identity with SEQ ID NO:1 and retains the ability to bind to ALDH4A1 protein.
[0010] Specifically, the nanobody further comprises framework regions FR1, FR2, FR3 and FR4; wherein the amino acid sequence of FR1 is shown in SEQ ID NO:2, the amino acid sequence of FR2 is shown in SEQ ID NO:4, the amino acid sequence of FR3 is shown in SEQ ID NO:6, and the amino acid sequence of FR4 is shown in SEQ ID NO:8.
[0011] In a second aspect, the present invention provides a gene sequence encoding the nanobody, the gene sequence comprising a nucleotide sequence as shown in SEQ ID NO:9.
[0012] Thirdly, the present invention provides a recombinant vector containing the gene sequence; the recombinant vector is an expression vector, selected from pMAL-c2x expression vector or pCANTAB-5E phage vector.
[0013] Fourthly, the present invention provides a host cell comprising the recombinant vector; the host cell is Escherichia coli TB1.
[0014] Fifthly, the present invention provides a method for preparing nanobodies for the detection of atherosclerosis, characterized by comprising the following steps: S1. Total RNA was extracted from peripheral blood mononuclear cells of camel species, and cDNA was obtained by reverse transcription. The heavy chain variable region single-domain antibody gene fragment was amplified by PCR, and a natural phage display library was constructed based on the heavy chain variable region single-domain antibody gene fragment. S2. Using the ALDH4A1 protein as a target, a biological panning was performed on the natural phage display library to screen out positive clones with the strongest binding signal. S3. The single-domain antibody gene fragment of the heavy chain variable region of the positive clone is cloned into the expression vector, transformed into host cells, induced to express, and purified to obtain nanobodies, namely anti-ALDH4A1 nanobodies.
[0015] Sixthly, the present invention provides the application of nanobodies in the preparation of reagents for detecting the ALDH4A1 content in plasma or in products for assisting in the diagnosis of atherosclerosis.
[0016] In a seventh aspect, the present invention provides a method for detecting the ALDH4A1 content in plasma, comprising the following steps: (1) Collect peripheral venous blood from the subject and separate the plasma; coat the nanobody described in any one of claims 1-3 onto an enzyme-linked immunosorbent assay (ELISA) plate as a capture antibody; (2) Plasma is added to the capture antibody, and enzyme-labeled detection antibody is added to form a double antibody sandwich complex; (3) Add the chromogenic substrate, according to OD 450 The value determines the ALDH4A1 content in plasma.
[0017] Eighthly, the present invention provides a kit containing the aforementioned nanobody.
[0018] Compared with the prior art, the beneficial effects achieved by the present invention are: (1) This invention screens and obtains anti-ALDH4A1 nanobodies that specifically bind to ALDH4A1 protein. These nanobodies are natural heavy chain variable region single-domain antibodies lacking the light chain, with a molecular weight of approximately 15 kDa and a binding affinity constant K for ALDH4A1 protein. aff Reaching 2.1×10 8 L / mol, IC50 50The concentration was 137.9 ng / mL. This nanobody specifically recognizes the ALDH4A1 protein and shows no cross-reactivity with non-target proteins such as BSA, OVA, TN, GFP, ApoB, and skim milk, providing a new antibody tool for the serological detection of atherosclerosis.
[0019] (2) This invention establishes a double-antibody sandwich ELISA detection system based on anti-ALDH4A1 nanobody. Using this nanobody as the capture antibody, the ALDH4A1 content in plasma can be quantitatively detected. The linear detection range of this detection system is 9.7~625 ng / mL, the limit of detection is 6.64 ng / mL, the average intra-assay recovery rate is 100.99±4.15%, the average inter-assay recovery rate is 102.19±8.99%, the average intra-assay coefficient of variation is 4.14%, and the average inter-assay coefficient of variation is 8.76%. All indicators meet the requirements of the YY / T1183-2024 industry standard and can be used for the quantitative detection of ALDH4A1 in clinical plasma samples.
[0020] (3) The anti-ALDH4A1 nanobody and detection system provided by this invention can be used for early screening and auxiliary diagnosis of atherosclerosis. Clinical plasma sample test results show that the ALDH4A1 level in the plasma of patients with atherosclerosis is higher than that in healthy controls, and the plasma ALDH4A1 concentration is positively correlated with the ApoB100 concentration (r=0.9534, p<0.0001). The nanobody of this invention has a small molecular weight, high stability, and is easy to recombine and express in Escherichia coli, providing a new technical means for the serological diagnosis of atherosclerosis. Attached Figure Description
[0021] Figure 1 The image shows the identification results of the purified ALDH4A1 protein.
[0022] Figure 2 The image shows the results of the assay for binding activity of phage-selected positive clones of nanobodies.
[0023] Figure 3 This is a sequence analysis diagram of the anti-ALDH4A1 nanobody.
[0024] Figure 4 Identification image of purified MBP-fused anti-ALDH4A1 nanobody.
[0025] Figure 5 The diagram shows the molecular docking results between the anti-ALDH4A1 nanobody and the ALDH4A1 protein.
[0026] Figure 6 Figure showing the results of optimized reaction conditions and affinity assays for the anti-ALDH4A1 nanobody.
[0027] Figure 7 The specificity and half-inhibition rate (IC50) of the anti-ALDH4A1 nanobody were measured. 50 Image showing the identification results.
[0028] Figure 8 The result of the standard curve of the anti-ALDH4A1 nanobody double antibody sandwich ELISA is shown.
[0029] Figure 9 The results of ALDH4A1 detection in atherosclerotic samples and its correlation analysis with ApoB100 are shown in the figure. Detailed Implementation
[0030] The technical solutions of the present invention will be clearly and completely described below with reference to the embodiments of the present invention. Obviously, the described embodiments are only some embodiments of the present invention, and not all embodiments. Based on the embodiments of the present invention, all other embodiments obtained by those of ordinary skill in the art without creative effort are within the scope of protection of the present invention.
[0031] Example 1: Preparation and Identification of ALDH4A1 Protein 1. Construction of recombinant plasmids: The human ALDH4A1 gene was cloned into the pCDNA3.1 eukaryotic expression vector to construct the pCDNA3.1-ALDH4A1-his recombinant plasmid; the cloning sites were Hind III and BamHI, and the C-terminus of the target gene was fused with a 6×his tag.
[0032] 2. Eukaryotic expression: 293F cells were fed at a rate of 1×10 6 Cells were seeded at a density of 1 / mL in serum-free medium and cultured at 37°C and 8% CO2 at 125-140 r / min in a shaker. The pCDNA3.1-ALDH4A1-his recombinant plasmid was transfected into 293F cells using the transfection reagent PEI and expressed in serum-free medium. The culture supernatant was collected and centrifuged to remove cell debris. After 96 h, the culture supernatant was loaded onto a Ni-NTA affinity chromatography column. Impurities were washed with equilibration buffer containing 20 mM imidazole and the target protein was eluted with elution buffer containing 500 mM imidazole. The elution peak was collected, dialyzed with PBS, and concentrated to obtain purified ALDH4A1 protein.
[0033] The molecular weight, purity, and immunoreactivity of the purified ALDH4A1 protein were identified by SDS-PAGE electrophoresis and Western blotting. The results are as follows: Figure 1 As shown.
[0034] Figure 1 The image shows the identification results of the purified ALDH4A1 protein. Among them, Figure 1 Figure A shows the SDS-PAGE electrophoresis result of purified ALDH4A1 protein. Figure 1 Figure B in the image shows a Western blot immunoblot image of purified ALDH4A1 protein detected using a his-tag antibody. Figure 1 As shown, the recombinant ALDH4A1 protein exhibits a specific band at the 62 kDa molecular weight position, with a protein purity greater than 90%. Western blotting results show that the protein can react with specific antibodies, confirming its good immunoreactivity and its suitability as an antigen for subsequent experiments.
[0035] Example 2: Screening, recombinant expression and performance identification of anti-ALDH4A1 nanobodies 1. Construction of VHH phage display library: Total RNA was extracted from peripheral blood mononuclear cells (PBMCs) of camels and cDNA was obtained by reverse transcription. The VHH variable region gene fragment was amplified by nested PCR, and the amplified product was cloned into the pCANTAB-5E phage vector. The amplified product was then electrotransformed into Escherichia coli TG1 competent cells to construct a VHH natural phage display library.
[0036] 2. Phage display and bioselection: Using the purified ALDH4A1 protein prepared in Example 1 as the target, the protein was diluted with carbonate buffer (pH 9.6) and coated into immunotubes. The coating was incubated at 4°C for 12 h. The coating solution was discarded, and the cells were washed with PBST and then blocked with skim milk powder. A phage display library was added and incubated. The supernatant was discarded and the cells were washed with PBST. The bound phages were eluted with glycine-HCl and immediately neutralized with Tris-HCl. The eluted phages were used to infect logarithmic-phase TG1 Escherichia coli, and after amplification, the cells were subjected to the next round of panning. The antigen coating concentration was gradually reduced in each round of panning to increase the screening pressure. The antigen coating concentration was 20 μg / mL in the first round of panning, and then decreased in each subsequent round until it was reduced to 1 μg / mL in the fourth round.
[0037] 3. Phage ELISA identification of positive clones: After screening, single clones were randomly selected for phage ELISA identification. The ELISA plate was coated with ALDH4A1 protein, blocked with skim milk powder, and incubated with phage supernatant. HRP-labeled anti-M13 antibody was added, followed by TMB color development. The incubation was terminated with 2M H2SO4, and OD was measured. 450 Value; select the clone with the strongest binding signal and name it A6, which is the anti-ALDH4A1 nanobody of the present invention.
[0038] Figure 2 The image shows the results of a phage display assay to determine the binding activity of panning nanobody positive clones. (Example:) Figure 2As shown, ELISA binding signals of multiple phage clones, A2, A3, A6, A7, A11, A17, A19, and A26, were detected, with clone A6 showing the highest OD. 450 The A6 clone was chosen because it had the highest numerical value and the strongest binding activity.
[0039] 4. Sequence analysis of anti-ALDH4A1 nanobody: The VHH of the anti-ALDH4A1 nanobody contains three complementarity-determining regions, CDR1, CDR2, and CDR3, and four framework regions, FR1, FR2, FR3, and FR4.
[0040] The amino acid sequence of the anti-ALDH4A1 nanobody is shown in SEQ ID NO.1: RQLVESGGGSVQAGGSLRLSCAASGYIARSYCMGWFRQAPGKEREGVAAIDTDGSSYADSVKGRFTISKDNAKNTLYLQMNSLKPEDTAMYYCAAECLGLPPLLVAYNYWGQGTQVTVSSEPKIPQPQP The amino acid sequence of FR1 is shown in SEQ ID NO.2: RQLVESGGGSVQAGGSLRLSCAAS The amino acid sequence of CDR1 is shown in SEQ ID NO.3: GYIARSYC The amino acid sequence of FR2 is shown in SEQ ID NO.4: MGWFRQAPGKEREGVAA The amino acid sequence of CDR2 is shown in SEQ ID NO.5: IDTDGSSY The amino acid sequence of FR3 is shown in SEQ ID NO.6: ADSVKGRFTISKDNAKNTLYLQMNSLKPEDTAMYYCAA The amino acid sequence of CDR3 is shown in SEQ ID NO.7: ECLGLPLLVAYNY The amino acid sequence of FR4 is shown in SEQ ID NO.8: WGQGTQVTVSSEPKIPQPQP The anti-ALDH4A1 nanobody consists of 384 bases, encoding 128 amino acids, namely FR1, CDR1, FR2, CDR2, FR3, CDR3, and FR4. The specific nucleotide sequence is shown in SEQ ID NO. 9. CGGCAGCTGGTGGAGTCTGGGGGAGGCTCGGTGCAGGCTGGAGGGTCTCTGAGACTCTCCTGTGCAGCCTCTGGATACATCGCCAGGAGCTACTGCATGGGCTGGTTCCGCCAGGCTCCAGGGAAGGAGCGCGAGGGGGTCGCAGCTATTGATACTGATGGTAGCAGCTACGCAGACTCCGTGAAGGGCCGA TTCACCATCTCCAAAGACAACGCCAAGAACACTCTGTATCTGCAAATGAACAGCCTGAAACCTGAGGACACTGCCATGTACTACTGTGCGGCAGAATGTTTGGGGTTGCCCCTTTTGGTTGCGTATAACTACTGGGGCCAGGGGACACAGGTCACCGTCTCCTCAGAACCCAAGATACCCCAACCACAACCA The nucleotide sequence of FR1 is shown in SEQ ID NO.10: CGGCAGCTGGTGGAGTCTGGGGGAGGCTCGGTGCAGGCTGGAGGGTCTCTGAGACTCTCCTGTGCAGCCTCT The nucleotide sequence of CDR1 is shown in SEQ ID NO.11: GGATACATCGCCAGGAGCTACTGC The nucleotide sequence of FR2 is shown in SEQ ID NO.12: ATGGGCTGGTTCCGCCAGGCTCCAGGGAAGGAGCGCGAGGGGGTCGCAGCT The nucleotide sequence of CDR2 is shown in SEQ ID NO.13: ATTGATACTGATGGTAGCAGCTAC The nucleotide sequence of FR3 is shown in SEQ ID NO.14: GCAGACTCCGTGAAGGGCCGATTCACCATCTCCAAAGACAACGCCAAGAACACTCTGTATCTGCAAATGAACAGCCTGAAACCTGAGGACACTGCCATGTACTACTGTGCGGCA The nucleotide sequence of CDR3 is shown in SEQ ID NO.15: GAATGTTTGGGGTTGCCCCTTTTGGTTGCGTATAACTAC The nucleotide sequence of FR4 is shown in SEQ ID NO.16: TGGGGCCAGGGGACACAGGTCACCGTCTCCTCAGAACCCAAGATACCCCAACCACAACCA Figure 3 This is a sequence analysis diagram of the anti-ALDH4A1 nanobody. Figure 3 As shown, the VHH core domain of the anti-ALDH4A1 nanobody consists of 119 amino acids. The anti-ALDH4A1 nanobody possesses the typical structure of a VHH antibody. Sequence alignment analysis using the IMGT / V-QUEST database revealed that the heavy chain variable region (VH) contains three hypervariable regions (CDRs): CDR1 (red region: GYIARSYC), CDR2 (yellow region: DTDGSSY), and CDR3 (purple region: ECLGLPLLVAYNY).
[0041] 5. Recombinant expression and purification of anti-ALDH4A1 nanobody: The VHH gene fragment of the anti-ALDH4A1 nanobody was subcloned into the pMAL-c2x expression vector to construct the pMAL-c2x-A6 recombinant expression plasmid, with an MBP tag fused to the N-terminus of the target gene. The recombinant plasmid was transformed into *E. coli* TB1 competent cells, and single colonies were picked and inoculated into LB medium. After culturing, the cells were collected, resuspended in lysis buffer, sonicated, and centrifuged to collect the supernatant. The supernatant was loaded onto a linear amylopectin affinity chromatography column, washed, and the target protein was eluted. The elution peak was collected to obtain the purified MBP-fused anti-ALDH4A1 nanobody. The results were identified by SDS-PAGE and Western blotting. Figure 4 .
[0042] Figure 4 This image shows the identification of the purified MBP-fused anti-ALDH4A1 nanobody. Figure 4 Image A in the middle is an SDS-PAGE electrophoresis image of the MBP-fused nanobody protein. Figure 4 Figure B in the middle section is a Western blot validation image of the nanobody fusion protein detected using MBP-tag antibody. (See figure below.) Figure 4 As shown, the MBP-fused anti-ALDH4A1 nanobody exhibited a specific target band at 58 kDa, confirming that the nanobody was successfully recombinantly expressed and purified in the E. coli system.
[0043] 6. Docking analysis between anti-ALDH4A1 nanobody and ALDH4A1 protein molecule: A three-dimensional structural model of the nanobody was constructed using AlphaFold. Protein-protein docking simulations were performed using the ALDH4A1 crystal structure as the acceptor and the anti-ALDH4A1 nanobody structure as the ligand, employing ZDOCK molecular docking software. The interaction forces and key residues at the binding interface were analyzed, and the results are shown in [Figure number missing]. Figure 5 .
[0044] Figure 5 This image shows the molecular docking results between the anti-ALDH4A1 nanobody and the ALDH4A1 protein. Figure 5 As shown in the figure, key interacting residues such as TYR-26 (CDR1), GLU-96 (CDR3), ALA105 (CDR3), and ASN-107 (CDR3) are marked. These key amino acid residues are all located inside the heavy chain complementarity-determining region of the nanobody. Molecular docking results show that the nanobody forms a stable binding interface with the surface of the ALDH4A1 protein through the CDR region. The CDR1 and CDR3 regions play a key role in the binding. These residues form hydrogen bonds with ALDH4A1, which enhances the stability and specificity of the antigen-antibody complex.
[0045] 7. Determination of the affinity between anti-ALDH4A1 nanobody and ALDH4A1 protein: Affinity was determined using an indirect ELISA method: ALDH4A1 protein was coated onto an ELISA plate at serial concentrations (0.03125–20 μg / mL); an equal volume of nanobody was added, and after incubation, HRP-labeled anti-tag secondary antibody was added. TMB was used for color development, and OD was measured. 450 Value; based on the binding curves at different antigen concentrations, the affinity constant K is calculated using the formula. aff The results are shown Figure 6 .
[0046] Figure 6 The figure shows the results of optimized reaction conditions and affinity assays for the anti-ALDH4A1 nanobody. Figure 6 Figure A shows a schematic diagram of the optimal reaction concentration of nanobodies and antigens determined using the checkerboard method. Figure 6 Figure B in the diagram shows the affinity assay results for anti-ALDH4A1 nanobodies at different antigen concentrations. Figure 6 As shown, the checkerboard heatmap determined the optimal working concentrations of ALDH4A1 protein and anti-ALDH4A1 nanobody; the affinity constant K of the nanobody was calculated using the curves. aff 2.1×10 8 L / mol demonstrates that the anti-ALDH4A1 nanobody possesses high antigen-binding capacity.
[0047] 8. Specificity and IC50 of anti-ALDH4A1 nanobody 50 Identification Specificity test: ALDH4A1 antigen and various non-target antigens (BSA, OVA, TN, GFP, ApoB, skim milk, etc.) were coated onto the enzyme-labeled plate, and anti-ALDH4A1 nanobodies were added. Cross-reactivity was detected by ELISA.
[0048] IC 50 Assay: A competitive ELISA (icELISA) was used. Anti-ALDH4A1 nanobody at a fixed concentration of 0.125 μg / mL was mixed with a series of concentrations of free ALDH4A1 (range 0.305–10000 ng / mL). The competitive inhibition curves were measured, and the IC50 was calculated. 50 Values, results are shown below Figure 7 .
[0049] Figure 7 The specificity and half-inhibition rate (IC50) of the anti-ALDH4A1 nanobody were measured. 50 Image of the identification results. Among them, Figure 7 Figure A shows the bar chart of ELISA detection of cross-reactivity between nanobodies and various antigens. Figure 7 Figure B shows the competitive ELISA inhibition curve. (For example...) Figure 7 As shown, only the target antigen ALDH4A1 has a high OD. 450 Signal values, OD values of BSA, OVA, TN, GFP, ApoB, and MILK (skim milk) 450 The signals remained at very low levels, indicating that the anti-ALDH4A1 nanobody could specifically recognize ALDH4A1 and hardly bind to other proteins. Figure 7 IC is calculated from the B-competitive binding curve. 50 =137.9 ng / mL, indicating that the nanobody has a strong binding ability to the ALDH4A1 antigen.
[0050] Example 3: Application of anti-ALDH4A1 nanobody in a double-antibody sandwich ELISA detection system 1. Establishment and validation of a double-antibody sandwich ELISA detection system A double-antibody sandwich ELISA method based on anti-ALDH4A1 nanobodies was established to achieve quantitative detection of ALDH4A1 in plasma.
[0051] Assay method: An ELISA plate (96-well plate) was coated with anti-ALDH4A1 nanobody as the capture antibody at 4°C for 12 h. After blocking with 5% skim milk powder, ALDH4A1 standards (0.1–10000 ng / mL) at various concentrations were added, and the plate was incubated at 37°C for 1 h. After washing, HRP-labeled detection antibody was added, and the plate was incubated at 37°C for 1 h. TMB was used for color development, and the reaction was terminated with 2M H2SO4. The OD was then measured. 450Absorbance value; plotted on the logarithm of ALDH4A1 concentration, OD 450 The values are plotted on the ordinate to create a standard curve, which determines the linear detection range and the minimum detection limit. The results are shown in [reference needed]. Figure 8 .
[0052] Figure 8 This is a standard curve diagram of the anti-ALDH4A1 nanobody double-antibody sandwich ELISA. Among them, Figure 8 Figure A shows the ELISA standard curves corresponding to different concentrations of ALDH4A1. Figure 8 Figure B in the diagram shows the linear range of ALDH4A1 concentration measured by ELISA. (See figure below.) Figure 8 As shown, OD 450 Absorbance increases with increasing ALDH4A1 antigen concentration; after logarithmic conversion of antigen concentration, a linear fitting curve is obtained, and within this range, OD... 450 With Log 10 The ALDH4A1 concentration showed a good linear correlation, and this double-antibody sandwich ELISA system can be used to quantitatively measure ALDH4A1 in samples.
[0053] Spike recovery experiment: Low, medium and high concentrations of ALDH4A1 standard (50, 100, 150 and 200 ng / mL) were added to the blocking solution sample, and four replicates were made for each concentration. Intra-batch (four replicates on the same day) and inter-batch (independent detection on four consecutive days) precision tests were performed. The recovery rate and coefficient of variation (CV) were calculated. The results are shown in Table 1.
[0054] Table 1
[0055] As shown in Table 1, the average intra-assay recovery rate of the double-antibody sandwich ELISA detection system of the present invention was 100.99±4.15%, the average inter-assay recovery rate was 102.19±8.99%, the average intra-assay coefficient of variation was 4.14%, and the average inter-assay coefficient of variation was 8.76%. All indicators meet the requirements of the industry standard "Enzyme-Linked Immunosorbent Assay Kit" (YY / T1183-2024) issued by the National Medical Products Administration on September 29, 2024 and implemented on October 15, 2025 (recovery rate 85~115%, intra-assay CV<10%, inter-assay CV<15%), proving that the detection system has good accuracy, stability and repeatability, and can be directly used for the quantitative detection of ALDH4A1 in clinical plasma samples.
[0056] 2. Correlation analysis between clinical plasma sample testing and disease The ALDH4A1 levels in the plasma of clinical atherosclerotic patients and healthy controls were detected using an established double-antibody sandwich ELISA detection system, and the correlation between ALDH4A1 levels and the severity of atherosclerosis was analyzed.
[0057] Test Methods: After ethical approval and informed consent, peripheral venous blood was collected from patients with atherosclerosis and age- and sex-matched healthy controls. The blood was anticoagulated with EDTA, centrifuged at 3000 r / min for 10 min to separate plasma, and stored at -80℃ for later use. The ALDH4A1 level in plasma was detected using the established double-antibody sandwich ELISA system. Plasma ApoB 100 levels were simultaneously detected using a commercially available ApoB 100 assay kit. Statistical analysis was performed using GraphPad Prism software. t-tests or ANOVA were used to determine statistical differences, and Pearson correlation analysis was used to assess the correlation between ALDH4A1 and ApoB 100. Results are shown below. Figure 9 .
[0058] Figure 9 The graph shows the detection results of ALDH4A1 in atherosclerotic samples and its correlation analysis with ApoB 100. Among them, Figure 9 Figure A shows a bar chart of plasma ALDH4A1 concentrations in healthy individuals and patients with atherosclerosis. Figure 9 Figure B in the diagram is a scatter plot showing the correlation between ALDH4A1 and ApoB100 concentrations. (For example...) Figure 9 As shown, the plasma ALDH4A1 level in patients with atherosclerosis was significantly higher than that in healthy controls, indicating that ALDH4A1 has the potential to serve as a disease detection indicator. ApoB 100 is a clinically recognized biomarker for atherosclerosis. The concentration of ALDH4A1 was significantly positively correlated with the concentration of ApoB 100 measured by commercially available kits, with a Pearson correlation coefficient of r = 0.9534 and p < 0.0001, proving that ALDH4A1 is a reliable indicator and indicating that ALDH4A1 can serve as a serological diagnostic biomarker for atherosclerosis, and its level is closely related to the severity of the disease.
[0059] Example 4: A kit for detecting ALDH4A1 levels in plasma, comprising: Capture antibody: Anti-ALDH4A1 nanobody, coated at a concentration of 1~5 μg / mL on 96-well microplate; ALDH4A1 standard: recombinant ALDH4A1 protein, lyophilized and stored after standardization; Chromogenic substrate: TMB single-component chromogenic solution; Termination solution: 2 mol / L H2SO4 solution; Washing buffer: PBST (PBS containing 0.05% Tween-20, 20× concentrate); Blocking solution: PBST containing 5% skim milk powder.
[0060] The kit of this invention has a detection linear range of 9.7~625 ng / mL, a limit of detection of 6.64 ng / mL, an intra-assay coefficient of variation of <10%, and an inter-assay coefficient of variation of <15%, which meets the industry standard YY / T1183-2024 and is suitable for the quantitative detection of ALDH4A1 in clinical plasma samples and the auxiliary diagnosis of atherosclerosis.
[0061] It will be apparent to those skilled in the art that the present invention is not limited to the details of the exemplary embodiments described above, and that the invention can be implemented in other specific forms without departing from its spirit or essential characteristics. Therefore, the embodiments should be considered in all respects as exemplary and non-limiting, and the scope of the invention is defined by the appended claims rather than the foregoing description. Thus, all variations falling within the meaning and scope of equivalents of the claims are intended to be included within the present invention. No markings in the claims should be construed as limiting the scope of the claims.
Claims
1. A nanobody for detecting atherosclerosis, characterized in that, It includes complementary determinant regions CDR1, CDR2, and CDR3; The amino acid sequence of CDR1 is shown in SEQ ID NO:3, the amino acid sequence of CDR2 is shown in SEQ ID NO:5, and the amino acid sequence of CDR3 is shown in SEQ ID NO:
7.
2. The nanobody according to claim 1, characterized in that, The amino acid sequence of the nanobody is as shown in SEQ ID NO:1, or an amino acid sequence that has at least 70%, 80%, 90%, 95% or 99% sequence identity with SEQ ID NO:1 and retains the ability to bind to ALDH4A1 protein.
3. The nanobody according to claim 1, characterized in that, The nanobody further comprises framework regions FR1, FR2, FR3 and FR4; wherein the amino acid sequence of FR1 is shown in SEQ ID NO:2, the amino acid sequence of FR2 is shown in SEQ ID NO:4, the amino acid sequence of FR3 is shown in SEQ ID NO:6, and the amino acid sequence of FR4 is shown in SEQ ID NO:
8.
4. A gene sequence encoding a nanobody according to any one of claims 1-3, comprising a nucleotide sequence as shown in SEQ ID NO:
9.
5. A recombinant vector comprising the gene sequence of claim 4.
6. A host cell comprising the recombinant vector of claim 5.
7. A method for preparing nanobodies as described in any one of claims 1-3, characterized in that, Includes the following steps: S1. Total RNA was extracted from peripheral blood mononuclear cells of camel species, and cDNA was obtained by reverse transcription. The heavy chain variable region single-domain antibody gene fragment was amplified by PCR, and a natural phage display library was constructed based on the heavy chain variable region single-domain antibody gene fragment. S2. Using the ALDH4A1 protein as a target, a biological panning was performed on the natural phage display library to screen out positive clones with the strongest binding signal. S3. The single-domain antibody gene fragment of the heavy chain variable region of the positive clone is cloned into the expression vector, transformed into host cells, induced to express, and purified to obtain nanobodies, namely anti-ALDH4A1 nanobodies.
8. The use of a nanobody as described in any one of claims 1-3 in the preparation of a reagent for detecting the ALDH4A1 content in plasma or a product for assisting in the diagnosis of atherosclerosis.
9. A method for detecting ALDH4A1 levels in plasma, comprising the following steps: (1) Collect peripheral venous blood from the subject and separate the plasma; coat the nanobody of any one of claims 1-3 onto an ELISA plate as a capture antibody; (2) Plasma is added to the capture antibody, and enzyme-labeled detection antibody is added to form a double antibody sandwich complex; (3) Add the chromogenic substrate, according to OD 450 The value determines the ALDH4A1 content in plasma.
10. A kit containing the nanobody according to any one of claims 1-3.
